Clinical trial
A Phase I-II Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Patients With Multiple Myeloma
NCT02353572 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I-II Study of Infusional Melphalan + Bortezomib for Myeloablative Therapy Prior to Autologous Transplant for Patients With Multiple Myeloma
- Lead sponsor
- University of Colorado, Denver
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- November 30, 2009
- Completion date
- September 30, 2011
- Enrollment
- 3 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
plasma cell myeloma, plasmacytosis, recurrent plasma cell myeloma, smoldering plasma cell myeloma